Literature DB >> 6492312

Antithrombin III deficiency as a reflection of dynamic protein metabolism in patients undergoing vascular reconstruction.

W R Flinn, M D McDaniel, J S Yao, V A Fahey, D Green.   

Abstract

Antithrombin III (AT-III) deficiency has been associated with increased risk of venous and arterial thromboses and arterial graft failure. Deficiency of this circulating glycoprotein may be congenital; however, acquired deficiencies may develop in protein-losing or protein-wasting states. In the present study, AT-III levels of 108 patients undergoing vascular surgical procedures were determined preoperatively and at intervals (third, fifth, and seventh days) postoperatively. The mean AT-III level was then compared to the patient's protein status. The effect of reduced AT-III activity on early graft failure was also noted. A low preoperative AT-III level (less than 80%) was found in 16.3% of the patients studied. Among 83 patients with serum albumin levels greater than 3.0 gm/dl or transferrin levels greater than 180 mg/dl, reduced AT-III activity was present in only 10 (12%). In contrast, when serum albumin levels were less than 3.0 gm/dl, AT-III deficiency was found in 12 of 25 patients (48%) (p less than 0.01). Early thrombosis of a femorodistal graft occurred in 5 of 15 patients (33%) with reduced AT-III levels. When AT-III levels were normal, early bypass failure occurred in only 9 of 67 grafts (13.4%). However, this difference was not statistically significant. An additional 15 patients had sequential pre- and postoperative measurements (up to 3 weeks) of serum protein and AT-III levels to illustrate the relationship between the dynamics of protein metabolism and AT-III levels. There was a clear temporal relationship between albumin, transferrin, and AT-III levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6492312

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  8 in total

1.  Prophylaxis against venous thromboembolism.

Authors:  J Richardson; S Sabanathan
Journal:  BMJ       Date:  1992-11-07

2.  Are the recommendations to use perioperative beta-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence?

Authors:  P J Devereaux; Salim Yusuf; Homer Yang; Peter T-L Choi; Gordon H Guyatt
Journal:  CMAJ       Date:  2004-08-03       Impact factor: 8.262

Review 3.  Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk.

Authors:  P J Devereaux; Lee Goldman; Deborah J Cook; Ken Gilbert; Kate Leslie; Gordon H Guyatt
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 4.  How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials.

Authors:  P J Devereaux; W Scott Beattie; Peter T-L Choi; Neal H Badner; Gordon H Guyatt; Juan C Villar; Claudio S Cinà; Kate Leslie; Michael J Jacka; Victor M Montori; Mohit Bhandari; Alvaro Avezum; Alexandre B Cavalcanti; Julian W Giles; Thomas Schricker; Homer Yang; Carl-Johan Jakobsen; Salim Yusuf
Journal:  BMJ       Date:  2005-07-04

Review 5.  The impact of inherited thrombophilia on surgery: a factor to consider before transplantation?

Authors:  Elias Kfoury; Ali Taher; Said Saghieh; Zaher K Otrock; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2008-05-31       Impact factor: 2.316

Review 6.  Factors contributing to success and failure of femorotibial bypass grafts.

Authors:  D F Courtney; W R Flinn; W J McCarthy; J S Yao; J J Bergan
Journal:  World J Surg       Date:  1988-12       Impact factor: 3.352

Review 7.  [Perioperative myocardial ischemia : Current aspects and concepts].

Authors:  B Bein; R Schiewe; J Renner
Journal:  Anaesthesist       Date:  2019-08       Impact factor: 1.041

8.  HIV-Associated Venous Thromboembolism.

Authors:  Michele Bibas; Gianluigi Biava; Andrea Antinori
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-07-08       Impact factor: 2.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.